Bayer completes acquisition of U.S. biologics manufacturing facility from Novartis

Bayer CO2 project among best ideas for the future

A Bayer project for using the greenhouse gas carbon dioxide as a component for plastics is among Germany’s most promising ideas for the future. The “Dream Production” research initiative is one of the award winners in this year’s “365 Landmarks in the Land of Ideas” competition. A pilot pla ... more

Bayer rated the most sustainable German company in its sector

Bayer's commitment to sustainability has gained special recognition: At the World Economic Forum in Davos, the rating agency SAM and the auditors KPMG presented their Sustainability Yearbook 2012, which named Bayer as the best German chemical company and one of only three enterprises in the ... more

Bayer MaterialScience builds multipurpose plant for coating raw materials

Bayer MaterialScience has begun construction of a multipurpose production plant for polyurethane coating raw materials at Chempark Leverkusen. The products hexamethylene diisocyanate (HDI) and isophorone diisocyanate (IPDI) are used primarily for high-quality and environmentally friendly au ... more

Bayer SA-NV

Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more

Bayer Corporation

Bayer Corporation, headquartered in Pittsburgh, is a subsidiary of Bayer AG, an international health care, nutrition and innovative materials group based in Leverkusen, Germany. In North America, Bayer had 2006 net sales of 7.8 billion euros and employed 17,200 at year end. Bayer’s three s ... more

Bayer Technology Services México

Bayer Technology Services stands for technological competence throughout the service life of processes or units. We support our customers from the development of innovative products and processes to engineering and construction of units, to operating control and optimization – with courage, ... more

Orion sues Sun Pharmaceuticals in the U.S. to enforce a patent for Stalevo

Orion Corporation has filed a patent infringement lawsuit in the United States to enforce its formulation patent, U.S. Patent No. 6,500,867, against Sun Pharmaceutical Industries Inc. and Sun Pharmaceutical Industries Limited, who seek to market generic versions of Stalevo® tablets (25/100/ ... more

Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing

Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was anno ... more

Bayer completes acquisition of U.S. biologics manufacturing facility from Novartis

Bayer Schering Pharma AG, Germany, has completed the acquisition of a biologics manufacturing facility in Emeryville, California from Novartis. Bayer will manufacture its multiple sclerosis drug Betaseron® at the Emeryville site, retain full control of all manufacturing and process technolo ... more

After a good third quarter: Bayer confirms Group outlook

The Bayer Group achieved further sales growth and significantly increased earnings in the third quarter of 2011. “It was a good quarter for Bayer,” Management Board Chairman Dr. Marijn Dekkers said Thursday at the presentation of the interim report. He described the continuing growth moment ... more

Bayer off to a successful start to 2011

The Bayer Group got off to a successful start to 2011. “All three subgroups contributed to the strong start to the year with sales and earnings increases,” Bayer CEO Dr. Marijn Dekkers explained on Thursday when the company’s first-quarter results were released. He was especially pleased at ... more

Bayer focuses resources on growth and innovation

Bayer plans to invest its resources even more systematically in growing the company and enhancing its innovative capability. The focus will be on researching, developing and marketing new products, particularly in HealthCare and CropScience, and on expanding activities in the emerging marke ... more

Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing

Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was anno ... more

Bayer completes acquisition of U.S. biologics manufacturing facility from Novartis

Bayer Schering Pharma AG, Germany, has completed the acquisition of a biologics manufacturing facility in Emeryville, California from Novartis. Bayer will manufacture its multiple sclerosis drug Betaseron® at the Emeryville site, retain full control of all manufacturing and process technolo ... more

Bayer HealthCare announces concrete plans for the global synergy goals and job cuts

Bayer HealthCare published concrete plans regarding the previously announced synergy goals. The integration of the activities of the former Schering AG, Germany, with the Pharma division of Bayer HealthCare shall result in annual savings of EUR 700 million from 2009. Adjustments to personne ... more